Current report, amended
Open the filing on sec.gov
Alzamend Neuro, Inc. (ALZN)
Nasdaq: ALZN · Pharmaceutical Preparations · Atlanta, GA · filing with the SEC since 2016
The companyfiscal 2026, as filed
Revenuen/a
Net income-$8.8M-94.3%
Earnings per share$-2.63+76.8%
Operating cash flow-$8.1M-22.8%
Cash$710,689-82.0%
Debtn/a
Shareholders’ equity$2.2M-44.6%
Shares, diluted3,337,143+640.3%
Return on equity-1196.4%
The recordfrom its filings
Filings in 202633
Newest filingNov 10 · 8-K/A
Annual reportJul 22, 2026
Quarterly reportSep 10, 2026
Next report due10-Q by Dec 15
Insider sales, 12 months$900,000
Insider buys, 12 months$300,000
Patents grantedn/a
Filer category<br>Emerging growth company
Trailing twelve months to Jul 2026Net income -$9.1MCash from operations -$6.8Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Registration withdrawal request
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report, amended
Open the filing on sec.gov
Insider trade report, amended
Open the filing on sec.gov
Preliminary proxy statement
Open the filing on sec.gov
Listing registration
Open the filing on sec.gov
Insider trade report, amended
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.